EpiVax leads NIH’s $5.8M bird-flu vaccine project

Updated at 10:21 a.m.

EPIVAX PRESIDENT AND CEO Dr. Anne S. De Groot. EpiVax has joined an National Institutes of Health partnership to research a vaccine for the influenza A (H7N9) virus. / PBN FILE PHOTO/MICHAEL SALERNO
EPIVAX PRESIDENT AND CEO Dr. Anne S. De Groot. EpiVax has joined an National Institutes of Health partnership to research a vaccine for the influenza A (H7N9) virus. / PBN FILE PHOTO/MICHAEL SALERNO
PROVIDENCE - Immunolgy engineering biotech firm EpiVax Inc. is leading a National Institutes of Health-funded $5.8 million collaboration developing a protective vaccine against avian influenza A(H7N9), identified by the Centers for Disease Control and Prevention as posing the greatest pandemic risk according to the CDC’s Influenza Risk Assessment Tool. In people, H7N9 can cause a severe form of pneumonia…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

No posts to display